Study wrapper · #1215
Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: A phase 3, randomized, active-controlled, multicenter, non-inferiority trial (WIN-IND study).
Editor's note
This is a properly registered, randomized non-inferiority trial of a biosimilar-style semaglutide, and the numbers line up: an HbA1c difference of 0.16 points with a confidence interval inside the pre-set margin, and no new safety signals over 24 weeks. The open-label design and modest size are limitations, but the primary endpoint is objective. The broader story is supply: semaglutide's patent position in India is eroding, and credible domestic versions will reshape pricing there. Worth publishing as a marker of that shift.
Plain-language abstract
In a phase 3 trial of 217 adults in India with type 2 diabetes not adequately controlled on metformin, a locally made version of semaglutide (from Intas) was compared head-to-head with the original Novo Nordisk product over 24 weeks. Both groups saw similar drops in HbA1c (about 1.5 percentage points), blood glucose, body weight, and BMI, and side-effect patterns were comparable. The trial met its bar for non-inferiority, meaning the copy performed about as well as the original — a result that matters mainly for drug pricing and access in India.